Type 1 Diabetes (T1D)

Metabolic Diseases
2
Pipeline Programs
5
Companies
5
Clinical Trials
3 recruiting
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
1
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

5 companies ranked by most advanced pipeline stage

Abbott
AbbottABBOTT PARK, IL
1 program
1
Sotagliflozin Low DosePhase 31 trial
Active Trials
NCT07211802Not Yet Recruiting52Est. Dec 2030
G
GentiBioMA - Cambridge
1 program
1
GNTI-122Phase 11 trial
Active Trials
NCT06919354Recruiting16Est. Feb 2028
Beta Bionics
Beta BionicsIRVINE, CA
1 program
Bionic PancreasN/A1 trial
Active Trials
NCT07011147Recruiting240Est. Apr 2029
Sanofi
SanofiPARIS, France
1 program
Centralized Monitoring ApproachN/A1 trial
Active Trials
NCT07322380Not Yet Recruiting1,000Est. Mar 2028
Deka Biosciences
Deka BiosciencesMD - Germantown
1 program
twiist Automated Insulin Delivery SystemN/A1 trial
Active Trials
NCT07356089RecruitingEst. May 2028

Trial Timeline

Clinical trial activity over time

2025
2026
2027
2028
2029
2030
AbbottSotagliflozin Low Dose
GentiBioGNTI-122
SanofiCentralized Monitoring Approach
Beta BionicsBionic Pancreas
Deka Biosciencestwiist Automated Insulin Delivery System

Clinical Trials (5)

Total enrollment: 1,308 patients across 5 trials

NCT07211802AbbottSotagliflozin Low Dose

CKM For Safe Use of SGLT2i in Type 1 Diabetes

Start: Jul 2026Est. completion: Dec 203052 patients
Phase 3Not Yet Recruiting
NCT06919354GentiBioGNTI-122

A Study of GNTI-122 in Adults Recently Diagnosed With T1D

Start: Sep 2025Est. completion: Feb 202816 patients
Phase 1Recruiting
NCT07322380SanofiCentralized Monitoring Approach

Feasibility and Adoption of a Screening Program for T1D Relatives in Canada

Start: Apr 2026Est. completion: Mar 20281,000 patients
N/ANot Yet Recruiting
NCT07011147Beta BionicsBionic Pancreas

Primary Care Pragmatic, Real World Experience for Automated Insulin Delivery

Start: Feb 2026Est. completion: Apr 2029240 patients
N/ARecruiting
NCT07356089Deka Biosciencestwiist Automated Insulin Delivery System

Twiist Postmarket Surveillance Study for Type 1 Diabetes

Start: Dec 2025Est. completion: May 2028
N/ARecruiting

Related Jobs in Metabolic Diseases

Manager, Patient Safety and Pharmacovigilance Operations

Kailera Therapeutics
Waltham, Massachusetts
8h ago

Senior Medical Science Liaison - Obesity - Northern CA, Central CA, NV

Amgen
California - San Francisco, US
Yesterday

(Sr) Scientist Analytical Chemistry – Mass Spectrometry (Temporary role 3 years)

Johnson & Johnson
Beerse, Antwerp, Belgium
2d ago

Computational Chemist

Topos Bio
San Francisco Office
2d ago

Associate Director, Legal Operations & Contracts Management

Kailera Therapeutics
Massachusetts
4d ago
From $155K/yr

Application & Integration Architect

Roche
Indianapolis
5d ago
$106K - $196K/yr

Phase Legend

Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available

Key Insights

1 late-stage (Phase 3) programs — potential near-term approvals
3 actively recruiting trials targeting 1,308 patients
5 companies competing in this space

Related Indications

Diabetes(737)Diabetes Mellitus, Type 2(485)Obesity(246)Type 2 Diabetes(207)Type 2 Diabetes Mellitus(190)Diabetes Mellitus(127)Diabetes Mellitus, Type 1(95)Type 1 Diabetes Mellitus(51)Type 1 Diabetes(50)Dyslipidemia(45)